Insider Selling: Alector, Inc. (NASDAQ:ALEC) Director Sells 10,500 Shares of Stock

Alector, Inc. (NASDAQ:ALEC) Director Paula Hammond sold 10,500 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $5.06, for a total value of $53,130.00. Following the completion of the transaction, the director now directly owns 60,209 shares of the company’s stock, valued at approximately $304,657.54. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Alector Stock Down 0.7 %

NASDAQ ALEC traded down $0.04 during trading hours on Tuesday, reaching $5.07. The company’s stock had a trading volume of 380,391 shares, compared to its average volume of 656,800. The firm’s 50-day moving average price is $5.09 and its 200-day moving average price is $5.58. Alector, Inc. has a 1 year low of $3.66 and a 1 year high of $8.90. The company has a market capitalization of $488.67 million, a price-to-earnings ratio of -3.64 and a beta of 0.72.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. The company had revenue of $15.08 million for the quarter, compared to analysts’ expectations of $16.04 million. Alector had a negative return on equity of 71.80% and a negative net margin of 125.11%. During the same period in the previous year, the firm earned $0.02 EPS. Equities research analysts anticipate that Alector, Inc. will post -1.93 EPS for the current fiscal year.

Institutional Trading of Alector

Hedge funds have recently modified their holdings of the company. Gladius Capital Management LP purchased a new stake in Alector during the 2nd quarter valued at $29,000. Allspring Global Investments Holdings LLC purchased a new stake in Alector during the 1st quarter valued at $40,000. Lazard Asset Management LLC purchased a new stake in Alector during the 1st quarter valued at $59,000. E Fund Management Co. Ltd. purchased a new stake in Alector during the 4th quarter valued at $81,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Alector by 89.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 18,403 shares of the company’s stock valued at $111,000 after buying an additional 8,670 shares during the period. 85.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Alector in a research note on Thursday, June 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alector in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $14.67.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.